Research Milestones
ROXI-ASPEN: From First Participant to Top 5: A Strong Start for Our Research Team
Our research team is celebrating an exciting early milestone! Just weeks after screening our first participant on June 26, 2026, our site reached the Top 5 screening sites in August. Reaching this milestone in such a short period of time reflects the dedication, collaboration, and hard work of everyone involved. From identifying potential participants and coordinating schedules to completing screenings and supporting participants throughout the process, each step requires a true team effort.
This achievement is especially meaningful as we continue building momentum and expanding opportunities for patients to participate in clinical research within our community. A big thank you to everyone who has contributed to this strong start. We are excited to see what we can accomplish together as the study continues!
Department of Surgery Research Update:
Reverser Study
The Department of Surgery continues to demonstrate strong performance in clinical research through its participation in the international Reverser study. The study is evaluating reversal of anticoagulation, an important area of investigation for the management of patients receiving anticoagulant therapy.
Carilion’s enrollment performance has been particularly notable. In just 12 months of being open to enrollment, Carilion has enrolled 13 participants, compared with other participating sites around the world that have been open for several years. Carilion is currently the sixth-highest enrolling site internationally, highlighting the strength of our clinical research infrastructure, investigator engagement, and study coordination.
The team’s performance has also received recognition from the study sponsor. Director of Research, Sydney Webb, received a Study Coordination Award recognizing a study coordinator who has gone above and beyond through strong organization, proactive problem solving, and dedication to quality execution.
Department of Medicine Research Update:
August 2026 saw the first participants enrolled to:
ACCLAIM-CTA (Cardiology; PI, L Wahid; Research Team Lead, Kristin Dunford)
This industry-sponsored trial investigates how lepodisiran affects the amount and type of plaque in the coronary blood vessels of adults who have high Lp(a) levels.
ALPINE (Dermatology; PI, Z Holcomb; Research Team Lead, MacKenzie Eubank) ALPINE looks at whether the new drug brepocitinib is safe and effective for the treatment of adult lichen planopilaris. In this uncommon autoimmune disease, overactive T cells attack normal hair follicles.
Congratulations Team!